UniProt ID | NFIL3_HUMAN | |
---|---|---|
UniProt AC | Q16649 | |
Protein Name | Nuclear factor interleukin-3-regulated protein | |
Gene Name | NFIL3 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 462 | |
Subcellular Localization | Nucleus . | |
Protein Description | Acts as a transcriptional regulator that recognizes and binds to the sequence 5'-[GA]TTA[CT]GTAA[CT]-3', a sequence present in many cellular and viral promoters. Represses transcription from promoters with activating transcription factor (ATF) sites. Represses promoter activity in osteoblasts (By similarity). Represses transcriptional activity of PER1 (By similarity). Represses transcriptional activity of PER2 via the B-site on the promoter (By similarity). Activates transcription from the interleukin-3 promoter in T-cells. Competes for the same consensus-binding site with PAR DNA-binding factors (DBP, HLF and TEF) (By similarity). Component of the circadian clock that acts as a negative regulator for the circadian expression of PER2 oscillation in the cell-autonomous core clock (By similarity). Protects pro-B cells from programmed cell death (By similarity).. | |
Protein Sequence | MQLRKMQTVKKEQASLDASSNVDKMMVLNSALTEVSEDSTTGEELLLSEGSVGKNKSSACRRKREFIPDEKKDAMYWEKRRKNNEAAKRSREKRRLNDLVLENKLIALGEENATLKAELLSLKLKFGLISSTAYAQEIQKLSNSTAVYFQDYQTSKSNVSSFVDEHEPSMVSSSCISVIKHSPQSSLSDVSEVSSVEHTQESSVQGSCRSPENKFQIIKQEPMELESYTREPRDDRGSYTASIYQNYMGNSFSGYSHSPPLLQVNRSSSNSPRTSETDDGVVGKSSDGEDEQQVPKGPIHSPVELKHVHATVVKVPEVNSSALPHKLRIKAKAMQIKVEAFDNEFEATQKLSSPIDMTSKRHFELEKHSAPSMVHSSLTPFSVQVTNIQDWSLKSEHWHQKELSGKTQNSFKTGVVEMKDSGYKVSDPENLYLKQGIANLSAEVVSLKRLIATQPISASDSG | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
11 | Acetylation | RKMQTVKKEQASLDA CCCHHHCHHHHCCCC | 51.20 | 26051181 | |
19 | Phosphorylation | EQASLDASSNVDKMM HHHCCCCCCCHHHHH | 23.32 | 25627689 | |
20 | Phosphorylation | QASLDASSNVDKMMV HHCCCCCCCHHHHHH | 42.46 | 25627689 | |
24 | Sumoylation | DASSNVDKMMVLNSA CCCCCHHHHHHHHHH | 25.31 | 28112733 | |
30 | Phosphorylation | DKMMVLNSALTEVSE HHHHHHHHHHEECCC | 22.09 | - | |
72 | Sumoylation | EFIPDEKKDAMYWEK CCCCHHHHHHHHHHH | 48.98 | - | |
72 | Sumoylation | EFIPDEKKDAMYWEK CCCCHHHHHHHHHHH | 48.98 | - | |
82 | Acetylation | MYWEKRRKNNEAAKR HHHHHHHHCCHHHHH | 69.06 | 7910691 | |
82 | Sumoylation | MYWEKRRKNNEAAKR HHHHHHHHCCHHHHH | 69.06 | - | |
104 | Ubiquitination | NDLVLENKLIALGEE HHHHHHHHHHHHCCC | 31.71 | - | |
116 | Ubiquitination | GEENATLKAELLSLK CCCCHHHHHHHHHHH | 35.15 | - | |
121 | Phosphorylation | TLKAELLSLKLKFGL HHHHHHHHHHHHHCC | 35.76 | 24719451 | |
152 | Phosphorylation | TAVYFQDYQTSKSNV CEEEEECHHCCCCCH | 11.69 | 29759185 | |
154 | Phosphorylation | VYFQDYQTSKSNVSS EEEECHHCCCCCHHH | 31.71 | 29759185 | |
155 | Phosphorylation | YFQDYQTSKSNVSSF EEECHHCCCCCHHHH | 20.68 | 29759185 | |
182 | Phosphorylation | CISVIKHSPQSSLSD HHHHHCCCCCCCCCC | 21.45 | 20873877 | |
185 | Phosphorylation | VIKHSPQSSLSDVSE HHCCCCCCCCCCCCC | 36.31 | 20873877 | |
186 | Phosphorylation | IKHSPQSSLSDVSEV HCCCCCCCCCCCCCC | 27.01 | 20873877 | |
199 | Phosphorylation | EVSSVEHTQESSVQG CCCCCEECCCCCCCC | 22.11 | 28348404 | |
202 | Phosphorylation | SVEHTQESSVQGSCR CCEECCCCCCCCCCC | 26.45 | 29116813 | |
203 | Phosphorylation | VEHTQESSVQGSCRS CEECCCCCCCCCCCC | 20.08 | 29116813 | |
207 | Phosphorylation | QESSVQGSCRSPENK CCCCCCCCCCCCCCC | 6.83 | 30576142 | |
210 | Phosphorylation | SVQGSCRSPENKFQI CCCCCCCCCCCCEEE | 40.67 | 30576142 | |
214 | Sumoylation | SCRSPENKFQIIKQE CCCCCCCCEEEEECC | 36.66 | 28112733 | |
219 | Sumoylation | ENKFQIIKQEPMELE CCCEEEEECCCCCHH | 50.68 | - | |
219 | Sumoylation | ENKFQIIKQEPMELE CCCEEEEECCCCCHH | 50.68 | 25114211 | |
242 | Phosphorylation | DRGSYTASIYQNYMG CCCCCEEEEEHHHCC | 17.65 | 27080861 | |
247 | Phosphorylation | TASIYQNYMGNSFSG EEEEEHHHCCCCCCC | 7.29 | 27080861 | |
251 | Phosphorylation | YQNYMGNSFSGYSHS EHHHCCCCCCCCCCC | 18.30 | 27080861 | |
253 | Phosphorylation | NYMGNSFSGYSHSPP HHCCCCCCCCCCCCC | 36.32 | 27080861 | |
255 | Phosphorylation | MGNSFSGYSHSPPLL CCCCCCCCCCCCCEE | 11.30 | 27080861 | |
256 | Phosphorylation | GNSFSGYSHSPPLLQ CCCCCCCCCCCCEEE | 22.48 | 27080861 | |
258 | Phosphorylation | SFSGYSHSPPLLQVN CCCCCCCCCCEEECC | 23.44 | 19276368 | |
267 | Phosphorylation | PLLQVNRSSSNSPRT CEEECCCCCCCCCCC | 32.68 | 30576142 | |
268 | Phosphorylation | LLQVNRSSSNSPRTS EEECCCCCCCCCCCC | 30.24 | 27732954 | |
269 | Phosphorylation | LQVNRSSSNSPRTSE EECCCCCCCCCCCCC | 42.44 | 30576142 | |
271 | Phosphorylation | VNRSSSNSPRTSETD CCCCCCCCCCCCCCC | 20.08 | 27732954 | |
274 | Phosphorylation | SSSNSPRTSETDDGV CCCCCCCCCCCCCCC | 34.01 | 30576142 | |
275 | Phosphorylation | SSNSPRTSETDDGVV CCCCCCCCCCCCCCC | 39.52 | 23927012 | |
277 | Phosphorylation | NSPRTSETDDGVVGK CCCCCCCCCCCCCCC | 38.87 | 28450419 | |
285 | Phosphorylation | DDGVVGKSSDGEDEQ CCCCCCCCCCCCCCC | 27.94 | 23401153 | |
286 | Phosphorylation | DGVVGKSSDGEDEQQ CCCCCCCCCCCCCCC | 53.79 | 25159151 | |
301 | Phosphorylation | VPKGPIHSPVELKHV CCCCCCCCCCCCCEE | 31.21 | 29255136 | |
306 | Sumoylation | IHSPVELKHVHATVV CCCCCCCCEEEEEEE | 30.03 | - | |
306 | Sumoylation | IHSPVELKHVHATVV CCCCCCCCEEEEEEE | 30.03 | 28112733 | |
311 | Phosphorylation | ELKHVHATVVKVPEV CCCEEEEEEEECCCC | 15.79 | 23312004 | |
314 | Sumoylation | HVHATVVKVPEVNSS EEEEEEEECCCCCCC | 47.97 | 28112733 | |
326 | Sumoylation | NSSALPHKLRIKAKA CCCCCCCHHHHCEEE | 37.21 | 28112733 | |
332 | Sumoylation | HKLRIKAKAMQIKVE CHHHHCEEEEEEEEE | 39.11 | 28112733 | |
337 | Sumoylation | KAKAMQIKVEAFDNE CEEEEEEEEEECCCC | 19.68 | - | |
337 | Sumoylation | KAKAMQIKVEAFDNE CEEEEEEEEEECCCC | 19.68 | 28112733 | |
350 | Sumoylation | NEFEATQKLSSPIDM CCHHHHHHCCCCCCC | 46.08 | 28112733 | |
350 | Ubiquitination | NEFEATQKLSSPIDM CCHHHHHHCCCCCCC | 46.08 | - | |
352 | Phosphorylation | FEATQKLSSPIDMTS HHHHHHCCCCCCCCC | 40.89 | 30266825 | |
353 | Phosphorylation | EATQKLSSPIDMTSK HHHHHCCCCCCCCCH | 35.99 | 29255136 | |
358 | Phosphorylation | LSSPIDMTSKRHFEL CCCCCCCCCHHHHEE | 27.61 | 30266825 | |
359 | Phosphorylation | SSPIDMTSKRHFELE CCCCCCCCHHHHEEC | 22.51 | 19691289 | |
360 | Ubiquitination | SPIDMTSKRHFELEK CCCCCCCHHHHEECC | 40.50 | - | |
360 | Sumoylation | SPIDMTSKRHFELEK CCCCCCCHHHHEECC | 40.50 | 28112733 | |
369 | Phosphorylation | HFELEKHSAPSMVHS HHEECCCCCCCCCCC | 53.60 | 29978859 | |
372 | Phosphorylation | LEKHSAPSMVHSSLT ECCCCCCCCCCCCCC | 32.90 | 29978859 | |
376 | Phosphorylation | SAPSMVHSSLTPFSV CCCCCCCCCCCCCEE | 18.68 | 29978859 | |
377 | Phosphorylation | APSMVHSSLTPFSVQ CCCCCCCCCCCCEEE | 22.76 | 29978859 | |
379 | Phosphorylation | SMVHSSLTPFSVQVT CCCCCCCCCCEEEEE | 25.00 | 29978859 | |
382 | Phosphorylation | HSSLTPFSVQVTNIQ CCCCCCCEEEEECCC | 16.91 | 29978859 | |
386 | Phosphorylation | TPFSVQVTNIQDWSL CCCEEEEECCCCCCC | 14.98 | 29978859 | |
392 | Phosphorylation | VTNIQDWSLKSEHWH EECCCCCCCCCCCEE | 33.92 | 29978859 | |
394 | Sumoylation | NIQDWSLKSEHWHQK CCCCCCCCCCCEEHH | 48.56 | - | |
394 | Sumoylation | NIQDWSLKSEHWHQK CCCCCCCCCCCEEHH | 48.56 | 28112733 | |
395 | Phosphorylation | IQDWSLKSEHWHQKE CCCCCCCCCCEEHHH | 39.73 | 29978859 | |
401 | Ubiquitination | KSEHWHQKELSGKTQ CCCCEEHHHHCCCCC | 47.97 | - | |
401 | Sumoylation | KSEHWHQKELSGKTQ CCCCEEHHHHCCCCC | 47.97 | 28112733 | |
406 | Sumoylation | HQKELSGKTQNSFKT EHHHHCCCCCCCEEC | 43.49 | 28112733 | |
406 | Sumoylation | HQKELSGKTQNSFKT EHHHHCCCCCCCEEC | 43.49 | - | |
406 | Ubiquitination | HQKELSGKTQNSFKT EHHHHCCCCCCCEEC | 43.49 | - | |
412 | Sumoylation | GKTQNSFKTGVVEMK CCCCCCEECCEEEEC | 44.16 | 28112733 | |
412 | Ubiquitination | GKTQNSFKTGVVEMK CCCCCCEECCEEEEC | 44.16 | - | |
412 | Sumoylation | GKTQNSFKTGVVEMK CCCCCCEECCEEEEC | 44.16 | - | |
413 | Phosphorylation | KTQNSFKTGVVEMKD CCCCCEECCEEEECC | 32.95 | 22468782 | |
419 | Ubiquitination | KTGVVEMKDSGYKVS ECCEEEECCCCCCCC | 34.92 | 21906983 | |
419 | Sumoylation | KTGVVEMKDSGYKVS ECCEEEECCCCCCCC | 34.92 | 28112733 | |
419 | Sumoylation | KTGVVEMKDSGYKVS ECCEEEECCCCCCCC | 34.92 | - | |
424 | Sumoylation | EMKDSGYKVSDPENL EECCCCCCCCCHHHC | 38.50 | - | |
424 | Ubiquitination | EMKDSGYKVSDPENL EECCCCCCCCCHHHC | 38.50 | 21906983 | |
424 | Sumoylation | EMKDSGYKVSDPENL EECCCCCCCCCHHHC | 38.50 | 28112733 | |
434 | Sumoylation | DPENLYLKQGIANLS CHHHCHHHHHHHHCC | 32.68 | 28112733 | |
434 | Ubiquitination | DPENLYLKQGIANLS CHHHCHHHHHHHHCC | 32.68 | - | |
441 | Phosphorylation | KQGIANLSAEVVSLK HHHHHHCCHHEEEHH | 23.38 | 28060719 | |
446 | Phosphorylation | NLSAEVVSLKRLIAT HCCHHEEEHHHHHHC | 33.09 | 28060719 | |
448 | Sumoylation | SAEVVSLKRLIATQP CHHEEEHHHHHHCCC | 37.34 | 28112733 | |
448 | Ubiquitination | SAEVVSLKRLIATQP CHHEEEHHHHHHCCC | 37.34 | - | |
459 | Phosphorylation | ATQPISASDSG---- HCCCCCCCCCC---- | 26.06 | 28450419 | |
461 | Phosphorylation | QPISASDSG------ CCCCCCCCC------ | 43.86 | 25159151 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of NFIL3_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of NFIL3_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of NFIL3_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
NC2B_HUMAN | DR1 | physical | 8836190 | |
MAFF_HUMAN | MAFF | physical | 23661758 | |
BATF_HUMAN | BATF | physical | 23661758 | |
NFIL3_HUMAN | NFIL3 | physical | 23661758 | |
TRAF2_HUMAN | TRAF2 | physical | 25416956 | |
AMOL2_HUMAN | AMOTL2 | physical | 25416956 | |
AMOL2_HUMAN | AMOTL2 | physical | 21516116 | |
RFWD2_HUMAN | RFWD2 | physical | 28514442 | |
STK40_HUMAN | STK40 | physical | 28514442 | |
CREB1_HUMAN | CREB1 | physical | 28514442 | |
ATF1_HUMAN | ATF1 | physical | 28514442 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-353, AND MASSSPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-301, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-301, AND MASSSPECTROMETRY. |